研究者業績

市川 裕菜

イチカワ ヒロナ  (Hirona Ichikawa)

基本情報

所属
武蔵野大学 薬学部

J-GLOBAL ID
201801000026794780
researchmap会員ID
B000290391

論文

 7
  • Tetsuyuki Takahashi, Yuri Ando, Hirona Ichikawa, Koichi Tsuneyama, Takao Hijikata
    The FEBS Journal in press 2023年4月  査読有り
  • Tetsuyuki Takahashi, Hirona Ichikawa, Yukiko Okayama, Manami Seki, Takao Hijikata
    Non-Coding RNA 8(4) 57-57 2022年7月  査読有り
    Virus-encoded microRNAs (miRNAs) target viral and host mRNAs to repress protein production from viral and host genes, and regulate viral persistence, cell transformation, and evasion of the immune system. The present study demonstrated that simian virus 40 (SV40)-encoded miRNA miR-S1 targets a cellular miRNA miR-1266 to derepress their respective target proteins, namely, T antigens (Tags) and telomerase reverse transcriptase (TERT). An in silico search for cellular miRNAs to interact with viral miR-S1 yielded nine potential miRNAs, five of which, including miR-1266, were found to interact with miR-S1 in dual-luciferase tests employing reporter plasmids containing the miRNA sequences with miR-S1. Intracellular bindings of miR-1266 to miR-S1 were also verified by the pull-down assay. These miRNAs were recruited into the Ago2-associated RNA-induced silencing complex. Intracellular coexpression of miR-S1 with miR-1266 abrogated the downregulation of TERT and decrease in telomerase activity induced by miR-1266. These effects of miR-S1 were also observed in miR-1266-expressing A549 cells infected with SV40. Moreover, the infected cells contained more Tag, replicated more viral DNA, and released more viral particles than control A549 cells infected with SV40, indicating that miR-S1-induced Tag downregulation was antagonized by miR-1266. Collectively, the present results revealed an interplay of viral and cellular miRNAs to sequester each other from their respective targets. This is a novel mechanism for viruses to manipulate the expression of viral and cellular proteins, contributing to not only viral lytic and latent replication but also cell transformation observed in viral infectious diseases including oncogenesis.
  • Misa Tokorodani†, Hirona Ichikawa†, Katsutoshi Yuasa, Tetsuyuki Takahashi, Takao Hijikata, †M.T, H.I. contributed equally to this study
    Biological and Pharmaceutical Bulletin 43(11) 1715-1728 2020年11月1日  査読有り筆頭著者
  • Tetsuyuki Takahashi, Hirona Ichikawa, Yuuki Morimoto, Koichi Tsuneyama, Takao Hijikata
    Biochemical and Biophysical Research Communication 516 388-396 2019年9月  査読有り
  • Hirona Ichikawa, Momoe Itsumi, Shunichi Kajioka, Tomoko Maki, Ken Lee, Makoto Tomita, Shoji Yamaoka
    Biochemical and Biophysical Research Communications 495(1) 64-70 2018年1月1日  査読有り筆頭著者
    Exchange protein directly activated by cAMP (EPAC) is a mediator of a cAMP signaling pathway that is independent of protein kinase A. EPAC has two isoforms (EPAC1 and EPAC2) and is a cAMP-dependent guanine nucleotide exchange factor for the small GTPases, Rap1 and Rap2. Recent studies suggest that EPAC1 has both positive and negative influences on cancer and is involved in cell proliferation, apoptosis, migration and metastasis. We report that EPAC1 and EPAC2 expression levels were significantly lower in bladder cancer tissue than in normal bladder tissue. In addition, bladder cancer cell lines showed reduced EPAC1 mRNA expression. Furthermore, EPAC1 overexpression in bladder cancer cell lines induced morphologic changes and markedly suppressed cell migration without affecting cell viability. The overexpressed EPAC1 preferentially localized at cell-cell interfaces. In conclusion, reduced EPAC1 expression in bladder tumors and poor migration of EPAC1-overexpressing cells implicate EPAC1 as an inhibitor of bladder cancer cell migration.
  • 市川 裕菜, 山岡 昇司, 梶岡 俊一, 逸見 百江
    日本癌学会総会記事 76回 J-3037 2017年9月  
  • Y. Saitoh, A. Hamano, K. Mochida, A. Kakeya, M. Uno, E. Tsuruyama, H. Ichikawa, F. Tokunaga, A. Utsunomiya, T. Watanabe, S. Yamaoka
    Leukemia 30(3) 716-727 2016年3月1日  査読有り
    Adult T-cell leukemia (ATL) arises from a human T-cell leukemia virus type I (HTLV-I)-infected cell and has few therapeutic options. Here, we have uncovered a previously unrecognized role for a ubiquitin-editing enzyme A20 in the survival of HTLV-I-infected cells. Unlike in lymphomas of the B-cell lineage, A20 is abundantly expressed in primary ATL cells without notable mutations. Depletion of A20 in HTLV-I-infected cells resulted in caspase activation, cell death induction and impaired tumorigenicity in mouse xenograft models. Mechanistically, A20 stably interacts with caspase-8 and Fas-associated via death domain (FADD) in HTLV-I-infected cells. Mutational studies revealed that A20 supports the growth of HTLV-I-infected cells independent of its catalytic functions and that the zinc-finger domains are required for the interaction with and regulation of caspases. These results indicate a pivotal role for A20 in the survival of HTLV-I-infected cells and implicate A20 as a potential therapeutic target in ATL.

書籍等出版物

 1
  • 市川 裕菜 (担当:分担執筆, 範囲:ポリオーマウイルス関連疾患とマイクロRNAによる治療戦略の項目)
    医学書院 2018年8月

講演・口頭発表等

 13

所属学協会

 2

共同研究・競争的資金等の研究課題

 1

資格・免許

 1
  • 件名
    薬剤師免許
    年月日
    2014